<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2015.54010</article-id><article-id pub-id-type="publisher-id">WJCR-16418</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20150400000_58820942.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  分子靶向药物与肿瘤
  Molecular Targeted Drugs and Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夏</surname><given-names>君燕</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>平</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>伍</surname><given-names>学强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>北京航天总医院肿瘤科，北京</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>xueqiangwu2001@163.com(伍学)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>11</month><year>2015</year></pub-date><volume>05</volume><issue>04</issue><fpage>65</fpage><lpage>73</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   依据已知肿瘤发生中涉及的异常分子或基因，设计针对这些特定分子和基因靶点的药物，选择性杀伤肿瘤细胞，这种治疗方法称为肿瘤的分子靶向治疗。目前分子靶向药物用于治疗乳腺癌、非小细胞肺癌、结直肠癌以及淋巴瘤、白血病等恶性肿瘤已取得令人瞩目的疗效。针对现有的治疗恶性肿瘤的分子靶向药物的作一综述。 According to the abnormal molecules or genes involved in the occurrence of the tumor, the drugs targeting these specific molecules and gene targets are designed, which are targeted to the tumor cells. This method of treatment is known as the molecular targeted therapy of tumor. At present, molecular targeted agents are used to treat breast cancer, non-small cell lung cancer, colorectal cancer, lymphoma, leukemia and other malignant tumors. The curative effect of these malignant tumors has been improved significantly. Molecular targeted agents for the treatment of malignant tumors will be described in this review.
    
  
 
</p></abstract><kwd-group><kwd>乳腺癌，非小细胞肺癌，结直肠癌，血液肿瘤，靶向治疗, Breast Cancer</kwd><kwd> Non Small Cell Lung Cancer</kwd><kwd> Colorectal Cancer</kwd><kwd> Blood Tumor</kwd><kwd> Targeted Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>分子靶向药物与肿瘤<sup> </sup></title><p>夏君燕，朱平，伍学强<sup>*</sup></p><p>北京航天总医院肿瘤科，北京</p><disp-formula id="hanspub.16418-formula314"><graphic xlink:href="http://html.hanspub.org/file/2-2150075x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2015年11月6日；录用日期：2015年11月20日；发布日期：2015年11月26日</p><disp-formula id="hanspub.16418-formula315"><graphic xlink:href="http://html.hanspub.org/file/2-2150075x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>依据已知肿瘤发生中涉及的异常分子或基因，设计针对这些特定分子和基因靶点的药物，选择性杀伤肿瘤细胞，这种治疗方法称为肿瘤的分子靶向治疗。目前分子靶向药物用于治疗乳腺癌、非小细胞肺癌、结直肠癌以及淋巴瘤、白血病等恶性肿瘤已取得令人瞩目的疗效。针对现有的治疗恶性肿瘤的分子靶向药物的作一综述。</p><p>关键词 :乳腺癌，非小细胞肺癌，结直肠癌，血液肿瘤，靶向治疗</p><disp-formula id="hanspub.16418-formula316"><graphic xlink:href="http://html.hanspub.org/file/2-2150075x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>恶性肿瘤已成为危及人类健康的第一杀手，随着检查技术的日新月异、人们对健康的重视程度的提高，肿瘤的检出率逐年增高，肿瘤疾病的种类繁多，致死、致畸率高。如何治疗肿瘤是全世界性的难题，目前公认的治疗方法：手术切除、术后化疗、放疗、靶向药物治疗及其他综合性治疗。靶向药物由于其以肿瘤组织为靶点，在肿瘤部位发挥作用，作用时间长，对正常组织影响小而具有较大的治疗优势，近年来发展迅速。</p></sec><sec id="s4"><title>2. 乳腺癌的靶向治疗</title><p>乳腺癌是女性的常见恶性疾病，其发病率逐年升高，并趋于年轻化，5年生存率达50%~60%，但复发率50%。HER-2在20%~30%的乳腺癌患者中过表达，过表达具有恶性程度高，病情进展快，生存率低等特点，是乳腺癌患者预后不良的指标[<xref ref-type="bibr" rid="hanspub.16418-ref1">1</xref>] 。</p><p>(1) 曲妥珠单克隆抗体是一类人源化单抗，其可以靶向作用于HER-2受体阻断HER-2基因表达，该抗体可以通过多种机制抑制肿瘤细胞的增殖，诱导肿瘤细胞死亡，目前具体机制尚不清楚。1998年，曲妥珠单抗首先被美国食品和药物管理局(FDA)批准的适应证即为HER-2阳性晚期乳腺癌的一线治疗[<xref ref-type="bibr" rid="hanspub.16418-ref2">2</xref>] 。目前，曲妥珠单抗已被批准用于乳腺癌术后辅助和转移性乳腺癌的治疗。Rugo等[<xref ref-type="bibr" rid="hanspub.16418-ref3">3</xref>] 对1023例HER-2阳性转移性乳腺癌患者一线及疾病进展后应用曲妥珠单抗的疗效进行了对比分析，研究结果证实对HER-2阳性的转移性乳腺癌患者而言，即使一线化疗 + 曲妥珠单抗治疗失败，在二、三线化疗基础上继续联合曲妥珠单抗仍然可以降低死亡风险。同时曲妥珠单抗联合化疗的新辅助治疗临床试验研究表明，HER-2阳性乳腺癌患者也可能会从术前曲妥珠单抗治疗中获益。在辅助化疗中，5项经典的临床试验(HERA [<xref ref-type="bibr" rid="hanspub.16418-ref4">4</xref>] 、NSABP B-31 [<xref ref-type="bibr" rid="hanspub.16418-ref5">5</xref>] 、NCCTG N9831 [<xref ref-type="bibr" rid="hanspub.16418-ref6">6</xref>] 、BCIRGO06 [<xref ref-type="bibr" rid="hanspub.16418-ref7">7</xref>] 、FinHerl5 [<xref ref-type="bibr" rid="hanspub.16418-ref8">8</xref>] )均显示曲妥珠单抗联合化疗能大大提高HER-2阳性患者的PFS (无进展生存期)和OS (总生存期)，显著降低46%~52%的复发风险。曲妥珠单抗治疗不但能使HER-2阳性的初治乳癌患者复发风险下降39%~52%，还能显著延长HER-2阳性复发乳癌患者的生存时间其对HER-2阳性患者的治疗具有重要意义。越来越多的研究显示曲妥珠单抗应用于HER-2阳性乳腺癌术后辅助和转移性乳腺癌以及术前的新辅助治疗、无论是单药还是联合用药甚至是复发的患者均可以改善患者的PFS和OS。但是曲妥珠单抗由于其心脏毒性、血液毒性、过敏、肝肾毒性等不良反应也限制了其广泛应用。</p><p>(2) 帕妥珠单抗是针对于HER-2胞外结构域人工合成的单克隆抗体，可阻止HER-2的自体二聚化和与其他受体形成异源二聚体并阻断其相关下游信号通路。I期和II期临床研究[<xref ref-type="bibr" rid="hanspub.16418-ref9">9</xref>] 证实，帕妥珠单抗具有明显的抗肿瘤效果，该药物可逆转HER-2阳性乳腺癌患者对曲妥珠单抗耐药[<xref ref-type="bibr" rid="hanspub.16418-ref10">10</xref>] 。</p><p>(3) 拉帕替尼是一种口服的小分子表皮生长因子酪氨酸激酶抑制剂，可同时与HER-1和HER-2的胞内区ATP位点结合从而抑制两个受体的酪氨酸激酶磷酸化，从而抑制肿瘤的生长。2007年已被FDA批准用于HER-2阳性既往曲妥珠单抗耐药的晚期和转移性乳腺癌。多项研究显示拉帕替尼单药治疗治疗乳腺癌脑转移[<xref ref-type="bibr" rid="hanspub.16418-ref11">11</xref>] 治疗炎性乳癌[<xref ref-type="bibr" rid="hanspub.16418-ref12">12</xref>] 治疗HER-2阳性的复发和晚期乳腺癌[<xref ref-type="bibr" rid="hanspub.16418-ref13">13</xref>] 或是联合紫杉醇[<xref ref-type="bibr" rid="hanspub.16418-ref14">14</xref>] 联合卡培他滨[<xref ref-type="bibr" rid="hanspub.16418-ref15">15</xref>] 联合曲妥珠单抗[<xref ref-type="bibr" rid="hanspub.16418-ref16">16</xref>] 均能使患者更多的获益。由于其对心脏的毒性较小，患者耐受性好，所以拉帕替尼治疗晚期复发或转移性、乳腺癌脑转移、炎性乳癌及曲妥珠单抗耐药的HER-2阳性患者具有很好的发展前景。</p><p>(4) PI3K/Akt/mTOR作为细胞内参与细胞增殖生长的调控的信号通路，与肿瘤的形成发展密切相关。同样PI3K/Akt/mTOR通路在乳腺肿瘤形成发展和肿瘤患者耐药性形成中的发挥重要作用。近年来发现雷帕霉素可以抑制乳腺癌细胞的增殖，但由于其溶解性差和不稳定性限制了其在肿瘤治疗中的应用[<xref ref-type="bibr" rid="hanspub.16418-ref17">17</xref>] 临床研究[<xref ref-type="bibr" rid="hanspub.16418-ref18">18</xref>] 数据表明，依维莫司作为另一类mTOR抑制剂可以抑制多种乳腺癌细胞的增殖，且进一步的I期和II期临床试验[<xref ref-type="bibr" rid="hanspub.16418-ref19">19</xref>] 证实其对晚期乳腺癌和转移性乳腺癌患者均具有良好的治疗效果。</p><p>(5) T-DM1是一种新型的抗体-药物偶联物，将曲妥珠单抗与一种干扰肿瘤细胞生长主要是强效抗微观蛋白的药物DM1相结合，特异性的将药物输送直肿瘤病灶使肿瘤缩小，延缓疾病进展。2013年FDA已批准该药作为治疗HER-2阳性晚期乳腺癌患者的药物，一项随机3期的国际研究EMILIA表明991例HER2阳性转移性乳腺癌患者接受T-DM1单药DFS和OS均优于拉帕替尼联合卡培他滨，有望成为HER-2阳性晚期乳腺癌的标准二线治疗药物。</p></sec><sec id="s5"><title>3. 非小细胞肺癌的靶向治疗</title><p>肺癌由于早期症状不典型，绝大部分肺癌患者发现时已经到了中晚期，无法手术治疗，全身综合治疗是主要的治疗手段，但是治疗效果并不理想。小细胞肺癌不到15%，余下均为非小细胞肺癌(NSCLC)。有研究结果显示，80%以上的中国晚期肺腺癌患者具有明确的肿瘤促进基因，并且97%的促进基因具有单一性，针对促癌基因研制的靶向药物成为晚期NSCLC治疗的新手段。临床上，表皮生长因子受体(epithelial growth factor receptor, EGFR)和棘皮动物微管结合蛋白样4(echinoderm micmtubule-associated protein-like 4, EML4)与间变淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因是目前最成熟的治疗靶点。在正常组织中，EGFR参与细胞的分裂分化，但在肿瘤组织中发生突变，参与肿瘤的发生发展和预后[<xref ref-type="bibr" rid="hanspub.16418-ref20">20</xref>] 。我国的一项研究[<xref ref-type="bibr" rid="hanspub.16418-ref21">21</xref>] 表明，在NSCLC中表皮生长因子受体(EGFR)的阳性表达率为53.1%~69.7%。且过高的EGFR表达往往提示NSCLC对常规的化疗药物(顺铂等)不敏感[<xref ref-type="bibr" rid="hanspub.16418-ref22">22</xref>] 。另一国外的PIONEER研究的结果显示，51.4%没有初期治疗的亚裔晚期肺腺癌患者具有EGFR基因的突变[<xref ref-type="bibr" rid="hanspub.16418-ref23">23</xref>] ，但在西方晚期肺腺癌患者中仅占17% [<xref ref-type="bibr" rid="hanspub.16418-ref24">24</xref>] 。所以对于中国的晚期肺腺癌患者，制定治疗方案前常规进行EGFR基因突变筛查尤为重要。</p><p>(1) 小分子酪氨酸酶抑制剂(TKI)是一些直接作用于EGFR受体，与ATP竞争性地结合EGFR特定结构域，抑制酪氨酸酶磷酸化，从而抑制下游信号传导，达到对肿瘤的抑制作用。代表药物有吉非替尼、厄洛替尼、埃克替尼等。IPASS研究结果显示，在EGFR基因敏感突变阳性的患者中，吉非替尼一线治疗组患者PFS明显长于化疗组，有效率达79%以上；而EGFR基因敏感突变阴性组则相反[<xref ref-type="bibr" rid="hanspub.16418-ref25">25</xref>] 。吉非替尼和厄洛替尼之间不存在交叉耐药，提示可以用于厄洛替尼治疗对吉非替尼耐药的NSCLC患者，目前主要作为晚期肺腺癌的二、三线治疗手段。有研究将埃克替尼和吉非替尼治疗晚期NSCLC的疗效和安全性进行比较研究，结果显示，埃克替尼组与吉非替尼组患者无论是EGFR基因敏感突变型或野生型患者，吉非替尼组与埃克替尼组患者的PFS、OS均无差别[<xref ref-type="bibr" rid="hanspub.16418-ref26">26</xref>] 。</p><p>(2) ALK是一种胰岛素样受体酪氨酸激酶。目前的研究[<xref ref-type="bibr" rid="hanspub.16418-ref27">27</xref>] 结果显示ALK参与形成的多种融合基因与多种肿瘤的发生密切相关。融合蛋白的形成可以激活细胞生长繁殖的细胞因子，有利于肿瘤细胞的生长繁殖。EML4-ALK融合基因在NSCLC中的阳性率约为3%~5%，克唑替尼是全球第一个小分子ALK和c-Met双靶点口服抑制剂，通过抑制EMIA-ALK融合蛋白，阻止ALK激酶区异常激活，达到抗肿瘤效应。PROFILEl005研究，客观缓解率为60%，中位PFS为8.1个月，且安全性良好[<xref ref-type="bibr" rid="hanspub.16418-ref28">28</xref>] 。EML4-ALK融合基因作为区别于EGFR和K-RAS突变而发现的新靶点，抗肿瘤机理上不同于以上，推测克唑替尼可能会用来治疗上述基因耐药的NSCLC患者。</p><p>(3) 越来越多的ALK阳性的NSCLC患者服用克唑替尼1~2年内出现对克唑替尼耐药或疾病进展，且中枢神经系统的复发进展较为常见，耐药主要原因为ALK融合基因拷贝数增加。色瑞替尼(Ceritinib)作为第二代口服ALK酪氨酸激酶抑制剂对晚期患者有高度活性，对表达EML4-ALK、NPM-ALK融合蛋白的细胞有抑制作用，能够克服克唑替尼耐药性，可以作为有ALK阳性转移且对克唑替尼进展或不能耐受的NSCLC患者的治疗。在临床前模型中，色瑞替尼抑制ALK的抗肿瘤效果是克唑替尼的20倍。色瑞替尼对ALK阳性NSCLC患者而言，具有快速，持续并且高活性的抗肿瘤作用。无论前期有无接受其他ALK抑制剂治疗，该药对于这类肿瘤患者确有疗效，目前已作为克唑替尼用药失败后的替代药物。</p></sec><sec id="s6"><title>4. 结直肠癌的靶向治疗</title><p>在中国结直肠癌发病率、死亡率仅次于肺、胃、肝癌位于第四位，每年近10万患者死于结直肠癌，且死亡率逐年增加，近2/3的患者发现时已有淋巴结或远处转移，晚期转移患者5年生存率&lt;10%，如何有效改善转移性结直肠癌患者的预后是亟待解决问题，近年来的分子靶向联合化疗治疗明显提高了晚期结直肠癌患者的生存期。靶向药物主要包括表皮生长因子受体(epidermal growth factor receptor, EGFR)抑制剂和血管内皮生长因子(vascular endothelial growth factor, VEGF)抑制剂。其中EGFR抑制剂是联合放疗的理想药物。60%~80%结直肠癌细胞表达EGFR，而EGFR与生存期负相关[<xref ref-type="bibr" rid="hanspub.16418-ref29">29</xref>] 。针对晚期结直肠癌的分子靶向药物贝伐单抗、西妥昔单抗、帕尼单抗已被批准用于临床。</p><p>(1) 西妥昔单抗作为EGFR代表药物，西妥昔单抗可与表皮生长因子受体(EGFR)胞外区域特异性结合，使EGFR表达下降，进而阻断酪氨酸激酶磷酸化及相关细胞内信号转导途径；抑制EGFR信号通路下游的RAS/RAF/MEK/ERK或者PI3K/PTEN/AKT信号通路来抑制肿瘤细胞的生长增殖[<xref ref-type="bibr" rid="hanspub.16418-ref30">30</xref>] 。在晚期结直肠癌中的单药作为二线、三线治疗仍有一定的有效率。联合化疗药物一线治疗晚期直肠癌II期临床研究证实西妥昔单抗联合FOLFIRI的疗效明显优于FOLFIRI 46.9% vs 38.7% [<xref ref-type="bibr" rid="hanspub.16418-ref31">31</xref>] 。西妥昔单抗治疗的有效性受其下游基因K-RAS状态的影响，K-RAS基因状态有2类型，野生型和突变型。野生型的KRAS基因受上游的EGFR信号调控。突变型，K-RAS蛋白处于持续活化状态，不受上游EGFR信号影响。因此即使应用EGFR拮抗剂阻断了EGFR信号转导，但突变的K-RAS不受影响仍然可以使下游信号活化，肿瘤细胞可以继续增殖和生长[<xref ref-type="bibr" rid="hanspub.16418-ref32">32</xref>] 。因此只有野生型K-RAS基因的患者才能从EGFR的治疗中获益，而突变型的患者则不能。近些年来，已发表的CRYSTAL、OPUS和CELIM等随机研究显示，K-RAS基因野生型者从西妥昔单抗联合化疗中获益更大，在2009年美国临床肿瘤学会(ASCO)上更新的CELIM研究进一步支持了KRAS野生型者可以从抗EGFR治疗中获益。2007年及2008年多项Ⅲ期临床研究的回顾性分析也显示，西妥昔单抗或帕尼单抗无论单药或联合化疗仅对K-RAS基因野生型的结直肠癌患者有效。K-RAS基因已成为第一个结直肠癌靶向治疗的重要分子标志物。目前在欧美等发达国家，K-RAS基因检测已经成为大肠癌患者治疗前必做的常规检查，K-RAS基因检测可以筛选出对抗EGFR靶向药物治疗有效的大肠癌患者，实现肿瘤病人的个体化治疗，从而达到良好的预后。早期检测K-RAS还可以通过该基因的状态了解到病人的复发转移风险，为将来选择最佳治疗做好准备。多个大样本临床试验评估了K-RAS突变对西妥昔单抗疗效的影响，例如一项国际Ⅲ期临床研究[<xref ref-type="bibr" rid="hanspub.16418-ref33">33</xref>] 在K-RAS野生型患者中，与单纯支持治疗相比，使用西妥昔单抗治疗可显著改善总生存期(9.5月vs 4.8月)和无进展生存期(3.7月vs 1.9月)。在K-RAS突变型患者中，西妥昔单抗治疗组和单纯支持治疗组的总生存期(4.5月vs 4.6月)和无进展生存期(均为1.8月)无显著差异。另一II期临床试验(OPUS试验) [<xref ref-type="bibr" rid="hanspub.16418-ref34">34</xref>] ，探讨西妥昔单抗联合FOLFOX一线治疗中K-RAS基因突变与疗效的关系。337例EGFR阳性的转移性结直肠癌初治患者中，233例检测K-RAS基因其中134例(58%)为野生型，99例(42%)为突变型。野生型患者西妥昔单抗联合FOLFOX的有效率和PFS分别为61%和7.7个月，单用FOLFOX方案分别为37%和7.2月；K-RAS基因突变型患者西妥昔单抗联合FOLFOX的有效率和PFS分别为33%和5.5个月，单用FOLFOX方案分别为49%和8.6个月。该研究显示对KRAS野生型患者一线西妥昔单抗联合FOLFOX治疗能获得良好的疗效，而K-RAS突变型患者加用西妥昔单抗未见疗效获益。NCCN已提出：1) 所有转移性结直肠癌患者都应检测K-RAS基因状态；2) 只有K-RAS野生型患者才建议接受EGFR抑制剂，如西妥昔单抗和帕尼单抗(包括单药或与化疗联合)治疗。晚期大肠癌患者不能进行K-RAS基因检测或者K-RAS基因突变型患者首先应该考虑抗血管内皮生长因子(VEGF)药物贝伐单抗治疗[<xref ref-type="bibr" rid="hanspub.16418-ref35">35</xref>] 。</p><p>(2) 贝伐单抗一种重组的入源化、人鼠嵌合抗VEGF的单克隆体抗体，贝伐单抗结合VEGF能够阻断血管发生信号的级联反应。在结直肠癌中约有50%以上患者肿瘤的VEGF表达阳性而在正常结直肠黏膜上皮和良性肿瘤中到几乎无表达。大量的临床试验证实贝伐单抗联合基础化疗药物能改善晚期结直肠癌患者的预后，并且OS和PFS均优于单独基础化疗药物。贝伐单抗用于化疗、西妥昔单抗治疗失败后的晚期大肠癌患者，仍然能够收到较好的疗效[<xref ref-type="bibr" rid="hanspub.16418-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.16418-ref37">37</xref>] 。</p><p>(3) 瑞格非尼是第一个被证实可用于治疗mCRC (转移性晚期结直肠癌)的小分子多激酶抑制剂，即使对于已接受过多种规范治疗，包括靶向治疗后仍出现病情进展的难治性mCRC患者，经瑞格非尼治疗后仍有可能取得生存获益，对于K-RAS基因突变型患者，瑞格非尼被证实同样具有抗肿瘤作用。无论在I、II、III期临床研究均显示强大的抗肿瘤活性，日本学者Sunakawa等[<xref ref-type="bibr" rid="hanspub.16418-ref38">38</xref>] 还证实了瑞格非尼在亚裔mCRC患者中的药物可耐受性和抗肿瘤活性。</p></sec><sec id="s7"><title>5. 血液肿瘤的靶向治疗</title><p>血液肿瘤发病率位于世界肿瘤总发病率的第六位，位居青少年死亡率之首。常规的放疗、化疗不能彻底杀灭肿瘤细胞，复发率高，且对周围组织器官影响大。全反式维甲酸、砷剂治疗APL，美罗华治疗NHL，伊马替尼治疗CML均取得了显著的疗效。</p><p>(1) 我国学者王振义院士成功的开导了维甲酸诱导分化治疗APL时代，使APL缓解率90%以上，随后的随机对照研究证实维甲酸联合基础化疗有85%的根治率。20世纪90年代我国血液学家又证实AS<sub>2</sub>O<sub>3</sub>单药治疗复发APL获得85%的缓解率，初诊缓解率达90%。目前维甲酸(ATRA)与砷剂(ATO)联合治疗作为急性早幼粒细胞白血病诊治首选方案，根治率达到90%以上。两者可作为APL患者诱导缓解治疗的一线药物，使APL的预后明显改善，CR率已达到90%以上，多数患者可望治愈[<xref ref-type="bibr" rid="hanspub.16418-ref39">39</xref>] 。</p><p>(2) 1997年FDA批准美罗华作为抗CD20抗原的单克隆抗体应用于CD20阳性的B细胞NHL的治疗，欧美国家的临床试验表明，美罗华联合化疗有效率达90%以上，且患者总生存期延长而不良反应无明显增加。年轻淋巴瘤患者可以从R-CHOP方案中获益，利妥昔单抗国际临床研究之一MIn T研究[<xref ref-type="bibr" rid="hanspub.16418-ref40">40</xref>] 纳入来自18个国家、172个研究单位的824例DLBCL患者。这些患者随机接受6个疗程CHOP或R-CHOP方案治疗后的CR率分别为68%和86%，3年EFS分别为59%和79%，3年OS率为84%和93%。此研究进一步证实了利妥昔单抗的治疗和提高CHOP方案药物敏感性的作用。法国成人淋巴瘤研究组(GELA)对399例60~80岁的老年初治DLBCL患者进行了8个周期CHOP或R-CHOP的随机临床试验。结果发现，R-CHOP组与CHOP组相比，CR率明显提高(76% vs 63%)；R-CHOP组5年生存率58%，而CHOP组为45% [<xref ref-type="bibr" rid="hanspub.16418-ref41">41</xref>] 。10年的随访结果显示，R-CHOP组10年生存率43.5%，而CHOP组仅27.6%，R-CHOP组的中位PFS期为4.8年，而CHOP组仅为1.2年。对于80岁以上的超高龄老年患者，法国和比利时联合进行了多中心的II期临床试验，应用R-mini CHOP (利妥昔单抗联合减低剂量的CHOP)方案治疗了153例患者，中位年龄为83岁，结果中位生存期为29个月，2年总生存率为59% [<xref ref-type="bibr" rid="hanspub.16418-ref42">42</xref>] 。利妥昔单抗联合CHOP，能显著增加总体反应率和完全缓解率，延长疾病进展时间[<xref ref-type="bibr" rid="hanspub.16418-ref43">43</xref>] 。可使B细胞淋巴瘤的总有效率可达到95% [<xref ref-type="bibr" rid="hanspub.16418-ref44">44</xref>] 。维妥珠单抗是第二代人源化抗CD20单抗，具有90%~95%的人抗体序列。具有较强的结合CD20的能力，非常低剂量的维妥珠单抗无论是静脉注射还是皮下注射，在短尾猴中都促进了B细胞的衰竭，在荷瘤小鼠中都控制了肿瘤的生长，进一步的临床实验正在进行中。奥法木单抗作为全人源化靶向抗CD20单抗体，具有新的CD20结合表位，与CD20亲和力更强，可快速、高效、持续的使外周B细胞耗竭，有研究[<xref ref-type="bibr" rid="hanspub.16418-ref45">45</xref>] 示难治的CLL病人在接受了第1次奥法木单抗输注后，B细胞数目降低的中值为23%，第8次输注后为降低92%，目前主要用于治疗慢性淋巴细胞白血病(CLL)。</p><p>(3) 慢性粒细胞白血病(CML)是最常见的骨髓增殖性肿瘤，具有特征性ph染色体t(9; 22)(q34; q11)转录翻译BCR-ABL融合蛋白。酪氨酸激酶抑制剂(TKI)是针对BCR-ABL融合蛋白的特异性靶向治疗药物。伊马替尼(IM)作为第一个应用于临床的TKI。2001年一项国际随机Ⅲ期临床试验(IRIS)以评价IM治疗初治CML慢性期的疗效，结果显示IM组完全血液学缓解率达97%，主要细胞遗传学缓解率达89%，完全细胞遗传学缓解率达82%，7年无事件生存(EFS)率8l%，无进展生存(PFS)率93% [<xref ref-type="bibr" rid="hanspub.16418-ref46">46</xref>] 。鉴于IM的卓越疗效，2008年国际上已公认IM 400 mg/d为CML慢性期的一线治疗方案，干扰素不再推荐作为CML的主要治疗选择，allo-HSCT也成为CML二线治疗的选择，CML的治疗进入了分子靶向治疗时代[<xref ref-type="bibr" rid="hanspub.16418-ref47">47</xref>] 。中国CML慢性期患者IM治疗血液学缓解率97.54%，其中完全血液学缓解率86.50%，12个月完全细胞遗传学缓解率接近70%，与既往国内单中心的报道相符，与国外的疗效接近，亦与HSCT的疗效相似，明显优于干扰素的疗效[<xref ref-type="bibr" rid="hanspub.16418-ref47">47</xref>] 。一项前瞻性研究[<xref ref-type="bibr" rid="hanspub.16418-ref48">48</xref>] 比较了初发CML慢性期患者接受IM和allo-HSCT(同胞HLA全相合异基因造血干细胞移)的结果，结果显示IM组和allo-HSCT组6年无疾病进展生存(PFS)率分别为96%和78%，6年总生存(OS)率分别为99%和79%，因此TKI在CML慢性期的应当作为首选。由于目前缺乏CML加速期、急变期选择二代TKI或allo-HSCT直接对比的数据，allo-SCT可以提供治愈疾病的机会，国内外均推荐TKI作为首选以对接allo-HSCT，这样会给患者带来最佳的治疗效果[<xref ref-type="bibr" rid="hanspub.16418-ref49">49</xref>] 。</p><p>分子靶向药物在乳腺癌、肺癌、结直肠癌、血液肿瘤等领域应用广泛，特别是近几年来联合化疗已明显改善患者的预后。越来越多的靶向药物正在被研制和应用多种肿瘤中，由于其服用方便，患者依从性好，不良反应较常规化疗轻，恶性肿瘤的治疗已进入靶向药物时代。但肿瘤的发生与发展是一个多基因参与的复杂的生物学过程，各个肿瘤发生过程不尽相同，参与肿瘤生长、增殖、存活过程的各种信号分子构成了复杂的网络，有时候控制其中一个靶点很难抑制肿瘤生长，且单一靶向药物易产生耐药性，研究肿瘤新靶点、开发多靶点抗肿瘤药，精准的靶向个体化疗治疗将是靶向药物研究的主导方向。同时靶向药物亦具有较多的毒性反应，包括心脏毒性、肺毒性、皮肤毒性、内分泌毒性、消化道毒性及过敏，如何在达到治疗目的的同时使不良反应减至最低将是今后研究的重点。</p></sec><sec id="s8"><title>文章引用</title><p>夏君燕,朱 平,伍学强. 分子靶向药物与肿瘤 Molecular Targeted Drugs and Tumors[J]. 世界肿瘤研究, 2015, 05(04): 65-73. http://dx.doi.org/10.12677/WJCR.2015.54010</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.16418-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Perez, E.A., Suman, V.J., Davidson, N.E., et al. (2006) HER2 Testing by Local Central and Reference Laboratories in Specimens from the North Central Cancer Treatment Group N9831 Inter Group Adjuvant Trial. Journal of Clinical Oncology, 24, 3032-3038. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2005.03.4744</mixed-citation></ref><ref id="hanspub.16418-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">安富荣. 曲妥珠单抗治疗转移性乳腺癌研究进展[J]. 中国肿瘤生物治疗杂志, 2002, 9(4): 70-72.</mixed-citation></ref><ref id="hanspub.16418-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rugo, H., Kaufman, P., Tan-Chiu, E., et al. (2008) Survival of Patients with HER-2(+)Metastatic Breast Cancer and Use of Trastuzumab Following Progression: Analysis of registHER. The 31st San Antonio Breast Cancer Symposium Proceedings, San Antonio, 10-14 December 2008.  
http://www.researchgate.net/publication/273894156_Survival_of_patients_with_HER2_metastatic_breast_&lt;br&gt;cancer_and_use_of_trastuzumab_following_progression_analysis_of_RegistHER</mixed-citation></ref><ref id="hanspub.16418-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Procter, M., Surer, T., de Azambuja, E., et al. (2010) Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology, 28, 3422-3428.</mixed-citation></ref><ref id="hanspub.16418-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tan-Chiu, E., Yothers, G., Romond, E., et al. (2005) Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, with or without Trastuzumab as Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31. Journal of Clinical Oncology, 23, 7811-7819.</mixed-citation></ref><ref id="hanspub.16418-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Russell, S.D., Blackwell, K.L., Lawrence, J., et al. (2010) Independent Adjudication of Symptomatic Heart Failure with the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials. Journal of Clinical Oncology, 28, 3416-3421.</mixed-citation></ref><ref id="hanspub.16418-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Slamon, D., Eiermann, W., Robea, N., et al. (2009) Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC-&gt;T) with Doxornbicin and Cyclophosphamide Followed by Doeetaxel and Trastuzumab (AC-&gt;TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2 Neu-Positive Early Breast Cancer Patients: BCIRG 006 Study. Cancer Research, 69, 62.</mixed-citation></ref><ref id="hanspub.16418-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Joensuu, H., Bono, P., Kataja, V., et al. (2009) Fluorouacil, Epirnbicin, and Cyclophosphamide with Either Doeetaxel or Vinorelbine, with or without Trastuzumab, as Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology, 27, 5685-5692.</mixed-citation></ref><ref id="hanspub.16418-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">De, P. and Leyland-Jones, B. (2005) Whither HER2-Related Therapeutics? Journal of Clinical Oncology, 28, 1091- 1096.</mixed-citation></ref><ref id="hanspub.16418-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Agus, D.B., Gordon, M.S., Taylor, C., et al. (2005) Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients with Advanced Cancer. Journal of Clinical Oncology, 23, 2534-2543.</mixed-citation></ref><ref id="hanspub.16418-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lin, N.U., Carey, L.A., Liu, M.C., Younger, J., Come, S.E., Ewend, M., et al. (2008) Phase II Trail of Lapatinib for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 26, 1993-1999. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.12.3588</mixed-citation></ref><ref id="hanspub.16418-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kaufman, B., Trudeau, M., Awada, A., Blackwell, K., Bachelot, T., Salazar, V., et al. (2009) Lapatinib Momotherapy in Patients with HER2-Overexpressing Relapsed or Refractory Inflammatory Breast Cancer: Final Results and Survival of the Expanded HER2+ Cohort in EGF103009, a Phase II Study. The Lancet Oncology, 10, 581-588.  
&lt;br&gt;http://dx.doi.org/10.1016/S1470-2045(09)70087-7</mixed-citation></ref><ref id="hanspub.16418-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Gomez, H.L., Doval, D.C., Chzvez, M.A., Ang, P.C.-S., Aziz, Z., Nag, S., et al. (2008) Efficacy and Safety of Lapatinib as First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 26, 2999-3005. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.14.0590</mixed-citation></ref><ref id="hanspub.16418-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jagiello-Gruszfeld, A., Tjulandin, S., Dobrovolsksys, N., Ma-nikhas, A., Pienkowski, T., DeSilvio, M., et al. (2010) A Single-Arm Phase II Trial of First-Line Paclitaxel in Combi-nation with Lapatinib in Her2-Overexpressing Metastatic Breast Cancer. Oncology, 79, 129-135. &lt;br&gt;http://dx.doi.org/10.1159/000318043</mixed-citation></ref><ref id="hanspub.16418-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, X., Cella, D., Cameron, D., Amonkar, M.M., Segreti, A., Stein, S., et al. (2009) Lapatinib plus Capecitabine versus Capecitabine Alone for HER2+ (ErbB2) Metastatic Breast Cancer: Quality-of-Life Assessment. Breast Cancer Research and Treatment, 117, 577-589. &lt;br&gt;http://dx.doi.org/10.1007/s10549-009-0310-8</mixed-citation></ref><ref id="hanspub.16418-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Stoniolo, A.M., Pegram, M.D., Overmoyer, B., Silverman, P., Peacock, N.W., Jones, S.F., et al. (2008) Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combi-nation with Trastumab in Patients with Advance ErbB2- Positive Breast Cancer. Journal of Clinical Oncology, 26, 3317-3323.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.13.5202</mixed-citation></ref><ref id="hanspub.16418-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hennessy, B.T., Lu, Y.L., Poradosu, E., Yu, Q.H., Yu, S.X., Hall, H., et al. (2007) Pharmacodynamic Markers of Perifosine Efficacy. Clinical Cancer Research, 13, 7421. &lt;br&gt;http://dx.doi.org/10.1158/1078-0432.CCR-07-0760</mixed-citation></ref><ref id="hanspub.16418-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ghayad, S.E., Vendrell, J.A., Larbi, S.B., Dumontet, C., Bieche, I. and Cohen, P.A. (2010) Endocrine Resistance Associated with Activated ErbB System in Breast Cancer Cells Is Reversed by Inhibiting MAPK or PI3K/Akt Signaling Pathways. International Journal of Cancer, 126, 545-562. &lt;br&gt;http://dx.doi.org/10.1002/ijc.24750</mixed-citation></ref><ref id="hanspub.16418-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sawyers, C.L. (2003) Will mTOR Inhibitors Make It as Cancer Drugs? Cancer Cell, 4, 343-348.  
&lt;br&gt;http://dx.doi.org/10.1016/S1535-6108(03)00275-7</mixed-citation></ref><ref id="hanspub.16418-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">FRYDW (1999) Inhibition of the Epidermal Growth Factor Receptor Family of Tyrosine Kinases as an Approach to Cancer Chemotherapy: Progression from Reversible to Irreversible Inhibitors. Pharmacology &amp; Therapeutics, 82, 207- 218. &lt;br&gt;http://dx.doi.org/10.1016/S0163-7258(98)00050-3</mixed-citation></ref><ref id="hanspub.16418-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">王洋, 梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展[J]. 临床医学工程, 2011, 18(2): 312-314.</mixed-citation></ref><ref id="hanspub.16418-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hirsch, F.R., Varella-Garcia, M., Bunn Jr., P.A., Di Maria, M.V., Veve, R., Bremnes, R.M., et al. (2003) Epidermal Growth Factor Receptor in Non-Small-Cell Lung Car-cinomas: Correlation between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 21, 3798-3807.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2003.11.069</mixed-citation></ref><ref id="hanspub.16418-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y., Au, J.S., Thongprasert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., et al. (2014) A Prosective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-162.  
&lt;br&gt;http://dx.doi.org/10.1097/JTO.0000000000000033</mixed-citation></ref><ref id="hanspub.16418-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kris, M.G., Johnson, B.E., Kwiatkowski, D.J., Iafrate, A.J., Wistuba, I.I., Aronson, S.L., et al. (2011) Identification of Driver Mutations in Tumor Specimens from 1,000 Pa-tients with Lung Adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology, 29, abstr CRA7506.</mixed-citation></ref><ref id="hanspub.16418-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mok, T.S., Wu, Y.L., Thongrasert, S., Yang, C.H., Chu, D.T., Saijo, N., et al. (2009) Gefitinib or Carboplatin-Pacli- taxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine, 361, 947-957.  
&lt;br&gt;http://dx.doi.org/10.1056/NEJMoa0810699</mixed-citation></ref><ref id="hanspub.16418-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Shi, Y.K., Zhang, L., Liu, X.Q., Zhou, C.C., Zhang, L., Zhang, S.C., et al. (2013) Icotinib versus Gefitinib in Previously Treated Advanced Non-Small-Cell Lung Cancer (ICOGEN): A Randomised, Double Blind Phase 3 Non-Infe- riority Trail. The Lancet Oncology, 14, 953-961. &lt;br&gt;http://dx.doi.org/10.1016/S1470-2045(13)70355-3</mixed-citation></ref><ref id="hanspub.16418-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kelleher, F.C. and McDermott, R. (2010) The Emerging Pathogenic and Therapeutic Importance of the Anaplastic Lymphoma Kinase Gene. European Journal of Cancer, 46, 2357-2368. &lt;br&gt;http://dx.doi.org/10.1016/j.ejca.2010.04.006</mixed-citation></ref><ref id="hanspub.16418-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D.W., Ahn, M.J., Shi, Y., De Pas, T.M., Yang, P.-C., Riely, G.J., et al. (2012) Results of a Global Phase II Study with Crizotinib in Advanced ALK-Positive Non-Small-Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, 30, abstr 7533.</mixed-citation></ref><ref id="hanspub.16418-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Khorana, A.A., Ryan, C.K., Cox, C., Eberly, S. and Sahasrabudhe, D.M. (2003) Vascular Endothelial Growth Factor, CD68, and Epidermal Growth Factor Receptor Expression and Survival in Patients with Stage II and Stage III Colon Carcinoma: A Role for the Host Response in Prognosis. Cancer, 97, 960-968. &lt;br&gt;http://dx.doi.org/10.1002/cncr.11152</mixed-citation></ref><ref id="hanspub.16418-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hebbar, M., Wacrenier, A., Desauw, C., Romano, O., Cattan, S., Triboulet, J.P. and Pruvot, F.R. (2006) Lack of Usefulness of Epidermal Growth Factor Receptor Expression Determination for Cetuximab Therapy in Patients with Colorectal Cancer. Anti-Cancer Drug, 17, 855-857. &lt;br&gt;http://dx.doi.org/10.1097/01.cad.0000217425.44584.9f</mixed-citation></ref><ref id="hanspub.16418-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Schmoll, H.J., Cartwright, T., Tabemero, J., Nowacki, M.P., Figer, A., Maroun, J., et al. (2007) Phase III Trail of Capecitabine plus Oxaliplatin as Adiuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. Journal of Clinical Oncology, 25, 102-109. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2006.08.1075</mixed-citation></ref><ref id="hanspub.16418-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">张晓东. 结直肠癌分子靶向治疗的进展[J]. 医学综述, 2009, 15(14): 2122-2123.</mixed-citation></ref><ref id="hanspub.16418-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Jonker, D.J., O’Callaghan, C.J., Karapetis, C.S., Zalcberg, J.R., Tu, D., Au, H.-J., et al. (2007) Cetuximab for the Treatment of Colorectal Cancer. The New England Journal of Medicine, 357, 2040-2048.  
&lt;br&gt;http://dx.doi.org/10.1056/NEJMoa071834</mixed-citation></ref><ref id="hanspub.16418-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Bokemeyer, C., Bondarenko, I., Hartmann, J.T., De Braud, F.G., Volovat, C., Nippgen, J., Stroh, C., Celik, I. and Koralewski, P. (2008) KRAS Status and Efficacy of First-Line Treat-ment of Patients with Metastatic Colorectal Cancer with FOLFOX with or without Cetuximab: The OPUS Experience (Abstract). Journal of Clinical Oncology, 26, 4000.</mixed-citation></ref><ref id="hanspub.16418-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, L., Eng, C., Nieman, L.Z., Kapadia, A.S. and Du, X.L. (2011) Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States from 1976 to 2005. American Journal of Clinical Oncology, 34, 573- 580. &lt;br&gt;http://dx.doi.org/10.1097/COC.0b013e3181fe41ed</mixed-citation></ref><ref id="hanspub.16418-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">万德森, 刘晖. 第十三届世界胃肠道肿瘤大会: 贝伐单抗治疗结直肠癌新进展[J]. 肿瘤研究与临床, 2012, 24(1): 1-3.</mixed-citation></ref><ref id="hanspub.16418-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">万德森. 贝伐单抗在转移性结直肠癌治疗中的应用[J]. 中国肿瘤临床, 2009, 36(23): 1374-1376.</mixed-citation></ref><ref id="hanspub.16418-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Sunakawa, Y., Furuse, J., Okusaka, T., Ikeda, M., Nagashima, F., Ueno, H., et al. (2013) Regorafenib in Japanese Patients with Solid Tumors: Phase I Study of Safety, Efficacy, and Pharmacokinetics. Investigational New Drugs, 32, 104-112. &lt;br&gt;http://dx.doi.org/10.1007/s10637-013-9953-8</mixed-citation></ref><ref id="hanspub.16418-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">焦力, 王书杰, 庄俊玲, 赵永强, 周道斌, 许莹, 韩冰, 张薇, 段明辉, 邹农, 朱铁楠, 沈悌. 亚砷酸和全反式维甲酸对急性早幼粒细胞白血病疗效和副作用的比较[J]. 中国医学科学院学报, 2009, 31(5): 555-558.</mixed-citation></ref><ref id="hanspub.16418-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Pfreundschuh, M., Trtimper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., et al. (2006) CHOP-Like Chemotherapy plus Rituximab versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the Mab Thera Intemational Trial (MInT) Group. The Lancet Oncology, 7, 379-391. &lt;br&gt;http://dx.doi.org/10.1016/S1470-2045(06)70664-7</mixed-citation></ref><ref id="hanspub.16418-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Fermé, C., et al. (2005) Long-Term Results of R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de I’Adulte. Journal of Clinical Oncology, 23, 4117-4126.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2005.09.131</mixed-citation></ref><ref id="hanspub.16418-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.-F., Castaigne, S., et al. (2011) Attenuated Immunochemotheragy Regimen (R-miniCHOP) in Elderly Patients Older than 80 Years with Diffuse Large B-Cell Lymphoma: A Multicenter Single-Arm Phase 2 Trail. The Lancet Oncology, 12, 460-468.  
&lt;br&gt;http://dx.doi.org/10.1016/S1470-2045(11)70069-9</mixed-citation></ref><ref id="hanspub.16418-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Tan, D. and Horning, S.J. (2008) Follicular Lymphoma: Clinical Features and Treatment. Hematology/Oncology Clinics of North America, 22, 863-882. &lt;br&gt;http://dx.doi.org/10.1016/j.hoc.2008.07.013</mixed-citation></ref><ref id="hanspub.16418-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Czuezman, M.S., Grillo-LoPez, A.J., White, C.A., Saleh, M., Gordon, L., LoBuglio, A.F., Jonas, C., Klippenstein, D., Dallaire, B. and Varns, C. (1999) Treatment of Patients with Low Grade B Cell Lymphoma with the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Che-motherapy. Journal of Clinical Oncology, 17, 268-276.</mixed-citation></ref><ref id="hanspub.16418-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Du, J.M., Yang, H., Guo, Y.J. and Ding, J.P. (2009) Structure of the Fab Fragment of Therapeutic Antibody of Atumumab Provides Insights into the Recognition Mechanism with CD20. Molecular Immunology, 46, 2419-2423.  
&lt;br&gt;http://dx.doi.org/10.1016/j.molimm.2009.04.009</mixed-citation></ref><ref id="hanspub.16418-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">O’rien, S.G., Guilhot, F., Goldman, J.M., et al. (2008) In-ternational Randomized Study of Interferon Reigns STl571 (IRIS) 7-Year Follow-Up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM). Blood, 112, abstr 186.</mixed-citation></ref><ref id="hanspub.16418-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">王建祥, 黄晓军, 吴德沛, 胡建达, 刘霆, 胡豫, 等. 中国15家医院慢性粒细胞白血病发病状况及目前诊断治疗模式调查分析[J]. 中华血液学杂志, 2009, 30(11): 721-725.</mixed-citation></ref><ref id="hanspub.16418-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Q., Xu, L.P., Liu, D.H., Liu, K.-Y., Gale, R.P., Zhang, M.-J., et al. (2013) Imatinib Results in Better Outcomes than HLA-Identical Sibling Transplants in Young Persons with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Leukemia, 27, 2410-2413. &lt;br&gt;http://dx.doi.org/10.1038/leu.2013.159</mixed-citation></ref><ref id="hanspub.16418-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">黄晓军. 慢性髓性白血病的过去、现在和未来[J]. 中华血液杂志, 2014, 35(2): 89-91.</mixed-citation></ref></ref-list></back></article>